Kaliico
Gd mrn..
Will keep an eye on MZON,Tks.
MFNX...what a ride a little while ago...
Heavy,heavy attack by shorts...
Took it from 36 + to 32 1/16 in about 5 min..
Now rebounded to about 35..Tried to buy but it
was moving to fast....Love this stock.....
XYBR holding very well....
I don,t remember who has ALLP but some good news today..
Down low, might be a play later on today..
I don't own this but I might buy some,,,News looks real good.
They got $$$$$$ and stock and future royalties.....
Any comments on this....
Banchee
Company Press Release
Alliance Pharmaceutical Corp. and Inhale
Therapeutic Systems Announce Completion of
PulmoSpheres Technology Transfer
SAN DIEGO and SAN CARLOS, Calif.--(BW HealthWire)--Nov. 8, 1999-- Alliance
Pharmaceutical Corp. (Nasdaq:ALLP - news) and Inhale Therapeutic Systems, Inc. (Nasdaq:INHL - news) announced today
that Alliance has transferred to Inhale rights to Alliance's PulmoSpheres® particle and particle processing technology and other
assets for use in respiratory drug delivery.
The PulmoSpheres technology is designed to enhance the efficiency and reproducibility of drugs delivered via propellant-based
metered-dose inhalers, dry powder inhalers, and other devices.
As payment for the technology transfer, Alliance has received $15 million in cash from Inhale, and $5 million worth of Inhale
stock. Alliance will also receive milestone payments based on the achievement of future defined events, plus additional royalty
payments based on eventual sales of a defined number of products commercialized using the technology.
Inhale has agreed that Alliance can commercialize two respiratory products that will be formulated by Inhale utilizing the
PulmoSpheres technology on a royalty-free basis. As partial consideration for $5 million worth of Alliance stock, Alliance has
retained the right to use the technology to develop products for drug delivery in conjunction with liquid ventilation, as well as an
unlimited number of PulmoSpheres-based non-respiratory products such as topical and injectable formulations.
Alliance Pharmaceutical Corp. is a research and development company with three products in late-stage clinical (human)
development, each addressing a different medical need. Oxygent(TM), an intravascular oxygen carrier (''blood substitute''), is
being assessed in international Phase 3 studies to reduce the need for donor blood transfusions in surgical patients. LiquiVent®,
an intrapulmonary ''liquid ventilation'' agent, is in pivotal Phase 2-3 studies in North America and Europe for treatment of acute
lung injury and acute respiratory distress syndrome. Imagent®, an ultrasound contrast agent being developed with Schering AG,
Germany, is the subject of a New Drug Application recently submitted to the U.S. Food and Drug Administration.
Inhale, located in San Carlos, Calif., is developing pulmonary delivery systems to create inhaleable drugs, including peptides and
proteins, for systemic and local lung indications. The company has tested six drugs in human clinical trials using its delivery
system and has feasibility and development partnerships with several pharmaceutical and biotechnology companies, including
Biogen, Centeon, Lilly, and Pfizer. Inhale's most advanced program is inhaleable insulin, which is in Phase III trials with Pfizer
Inc. and Hoechst Marion Roussel.
Except for historical information, the matters set forth in this release are forward-looking statements that are subject to risks and
uncertainties that could cause actual results to differ materially from those set forth herein, including the availability of funding for
development, the uncertainties associated with the conduct of preclinical or clinical studies and the timing or ability to investigate
scientific data. Alliance refers you to cautionary information contained in documents the Company files with the Securities and
Exchange Commission from time to time, including the last Form 10-K, and those risk factors set forth in the most recent
registration statement on Form S-3 (File No. 333-76343).
Contact:
Alliance Pharmaceutical Corp.
Gwen Rosenberg, 858/410-5275
or
Inhale Therapeutic Systems Inc.
Joyce Strand, 650/631-3138 |
